Compare Natera Inc. Common Stock (NTRA) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Health Care Select Sector SPDR Fund — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Health Care Select Sector SPDR Fund trades at $176.22 (market cap $44.49B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Natera Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| NTRA | XLV | |
|---|---|---|
Market Cap | $57.03B | $44.49B |
Volume | 1,131,157 | 8,745,019 |
Sector | Health | — |
52-Week High | $425.64 | $175.68 |
52-Week Low | $179.42 | $142.33 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
XLV trades at $169.66, down 1.35% on the day, while maintaining a bullish technical outlook with strong moving average support. The healthcare ETF's low 0.08% expense ratio and diversified exposure to 60 S&P 500 healthcare stocks provide cost-effective sector access. Recent news highlights XLV's defensive characteristics during potential Fed rate hikes and its competitive positioning against peer healthcare ETFs.
The ETF offers defensive growth exposure with healthcare sector stability, though elevated RSI levels suggest near-term consolidation. Political volatility and pharmaceutical trial failures present sector-specific risks, while XLV's technical strength and institutional interest support continued upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
